Literature DB >> 11738342

Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia.

E Visconti1, E Ortona, P Mencarini, P Margutti, S Marinaci, M Zolfo, A Siracusano, E Tamburrini.   

Abstract

The purpose of this study was to determine whether dihydropteroate synthase gene (DHPS) mutations were associated with the failure of sulpha/sulphone drugs used as prophylaxis agents in HIV infected patients. Results suggested that DHPS mutations were significantly associated with failure of anti-Pneumocystis carinii sulphone prophylaxis (P=0.031). An increasing number of mutant P. carinii strains have been isolated from patients no longer having prophylaxis. There was no statistically significant difference in severity or outcome of the pneumonia caused by wild-type or mutant DHPS. Moreover, two of the three patients with mutant P. carinii pneumonia (PCP) were successfully treated with sulpha drugs. We think that P. carinii drug-resistance could be an emerging problem for immunocompromised patients including those with HIV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738342     DOI: 10.1016/s0924-8579(01)00460-5

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  A Quantitative Model to Estimate Drug Resistance in Pathogens.

Authors:  Frazier N Baker; Melanie T Cushion; Aleksey Porollo
Journal:  J Fungi (Basel)       Date:  2016-12-05

2.  Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.

Authors:  Peter Iliades; Steven R Meshnick; Ian G Macreadie
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Dihydropteroate synthase and novel dihydrofolate reductase gene mutations in strains of Pneumocystis jirovecii from South Africa.

Authors:  F J L Robberts; L J Chalkley; K Weyer; P Goussard; L D Liebowitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

4.  Dihydropteroate synthase mutations in Pneumocystis jiroveci can affect sulfamethoxazole resistance in a Saccharomyces cerevisiae model.

Authors:  Peter Iliades; Steven R Meshnick; Ian G Macreadie
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 5.  Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia.

Authors:  Cheryl R Stein; Charles Poole; Powel Kazanjian; Steven R Meshnick
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

Review 6.  Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance.

Authors:  Laurence Huang; Kristina Crothers; Chiara Atzori; Thomas Benfield; Robert Miller; Meja Rabodonirina; Jannik Helweg-Larsen
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

Review 7.  Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.

Authors:  Thomas R Rogers; Paul E Verweij; Mariana Castanheira; Eric Dannaoui; P Lewis White; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

8.  Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia.

Authors:  Meja Rabodonirina; Laetitia Vaillant; Patrick Taffé; Aimable Nahimana; René-Pierre Gillibert; Philippe Vanhems; Philippe M Hauser
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

9.  Pneumocystis jirovecii dihydropteroate synthase genotypes in immunocompetent infants and immunosuppressed adults, Amiens, France.

Authors:  Anne Totet; Sophie Latouche; Philippe Lacube; Jean-Claude Pautard; Vincent Jounieaux; Christian Raccurt; Patricia Roux; Gilles Nevez
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.